Eton Pharmaceuticals, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Eton Pharmaceuticals announced commercial availability of IMPAVIDO (miltefosine) capsules for leishmaniasis treatment in the United States, acquired exclusive commercialization rights, and established distribution through Anovo Specialty Pharmacy. The company integrated its Eton Cares patient support program offering $0 co-pay for eligible commercially insured patients and expanded patient assistance programs.
Why this rating
IMPAVIDO is a real addition to Eton's rare disease portfolio (now 11 commercialized products), with established distribution and patient support infrastructure. However, leishmaniasis is ultra-rare in the U.S. (low patient volume), limiting revenue scale relative to the $361M market cap. Moderate significance for a small-cap rare disease company.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.